Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement
Cellectis bioresearch, subsidiary of Cellectis, and Lonza announced that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.
Cellectis bioresearch will use its meganucleases to deactivate (knock-out) the glutamine synthetase (GS) in CHOK1SV, Lonza’s proprietary host cell line. Meganucleases are molecular scissors that can be directed to a single highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene function.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.